Tirzepatide
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.
Off-label semaglutide, tirzepatide lower HbA1c, weight in type 1 diabetes
Adults with type 1 diabetes have greater reductions in body weight and HbA1c after using off-label semaglutide or tirzepatide than those not using either drug, according to data published in Diabetes Technology & Therapeutics.
FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced.
Top in endocrinology: BP benefits of low-cal keto diet; tirzepatide reduces albuminuria
Researchers found that women with hypertension who followed a very low-calorie ketogenic diet had lower systolic and diastolic blood pressure at 6 months than those who participated in intermittent fasting or had no dietary restrictions.
Tirzepatide reduces albuminuria among adults with type 2 diabetes in SURPASS trials
Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy, researchers reported.
Most adults with overweight or obesity discontinue GLP-1 therapy within 2 years
More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported in JAMA Network Open.
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with an increase in online searches for obesity drugs, according to data published in JAMA Network Open.
Obesity medications can tackle metabolic cardiorenal disease
The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, cardiovascular disease and overall mortality are well known.
Obesity medications can tackle metabolic cardiorenal disease
In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, CVD and overall mortality.
Dietitians should take the lead in weight management for patients with kidney disease
Registered dietitian nutritionists caring for patients with chronic kidney disease are frequently challenged to help address multiple chronic diseases, comorbidities and acute issues to achieve goals for health and well-being.